



e-therapeutics plc
("e-therapeutics" or the "Company")

Commencement of trading on the OTCQX Best Market in the United States

Oxford, UK, 24 September 2021 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces that trading in the Company's Ordinary Shares of nominal value of £0.001 each ("Ordinary Shares") will begin trading today on the OTCQX Best Market ("OTCQX") in the United States ("U.S."), under the ticker symbol "ETXPF".

By trading on the premium OTCQX, e-therapeutics' shares will be available to U.S. investors during U.S. working hours and priced in U.S. dollars and there is the potential to increase the liquidity in e-therapeutics' shares on AIM. The OTCQX is designed for established companies. Foreign Private Issuers, such as e-therapeutics, that trade on the OTCQX are exempt under the U.S. Exchange Act Rule 12g3-2(b) from SEC reporting if they make information that is required by their home market regulator publicly available to U.S. investors in English. e-therapeutics will therefore face no extra reporting obligations and incur minimal ongoing costs as a result of the Company's Ordinary Shares being traded on the OTCQX. Through OTC Link® ATS and OTC Link ECN, the OTC Market Group Inc. connects to a diverse network of broker-dealers that provide liquidity and execution services.

B. Riley Securities acted as the Company's OTCQX sponsor.

e-therapeutics' Ordinary Shares will continue to trade on the London Stock Exchange's AIM Market under the symbol "ETX".

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: *"Trading on OTCQX is an important step for e-therapeutics to broaden the Company's shareholder base. U.S. institutional and retail investors will now be able to buy and sell our shares via online trading platforms and mobile apps. We believe that our computational biology and RNAi therapeutics platforms are particularly suited to a global audience and we look forward to sharing our equity story with an international audience."*

Jonathan Dickson, Vice President at OTC Markets Group commented: *"We are delighted to welcome e-therapeutics to the OTCQX Market. Cross-trading on OTCQX will enable e-therapeutics, listed on the LSE AIM Market, to expand its U.S. investor base. We look forward to providing the Company and its investors with a transparent and efficient trading experience and all the benefits of our premium public market."*

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO
Karl Keegan, CFO

Tel: +44 (0)1993 883 125
www.etherapeutics.co.uk

SP Angel Corporate Finance LLP
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an *in silico* laboratory that enables the rapid screening of millions of compounds and the identification of small subsets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.